Clinical Trials Browser

Phase 1/2 × sugemalimab × Clear all

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04194801 2023-02-06

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Phase 1/2 Completed

26 enrolled 31 charts

Gastrointestinal

Carcinoma, Hepatocellular